HPLC Tracks Bupivacaine Nanoparticles for Pain

Long-lasting nerve pain places a heavy burden on patients and on society, and opioid painkillers are not a good long-term option because they can be addictive. To find a better approach, researchers packed bupivacaine, a local anesthetic, into tiny particles made from a biodegradable material. The idea was that the particles would release the drug slowly, providing longer-lasting pain relief while reducing the risk of harmful side effects throughout the body.

The team tested how well this worked in rats with two different types of nerve injury that mimic chronic nerve pain in people. They used a powerful microscope to examine the shape and size of the particles and an X-ray technique to check how the drug was spread throughout them. To understand how the treatment relieved pain, they recorded electrical signals from nerve cells near the spine and from the sciatic nerve, which runs down the leg. They also measured how much of the drug reached the bloodstream using high-performance liquid chromatography (HPLC). The team published their findings in the journal Pharmaceutics.¹

Why Are Doctors Looking for Alternatives to Opioids for Surgical Pain, and How Might Nanotechnology Help?

Managing pain is a key part of caring for patients before, during, and after surgery. Opioid painkillers work very well for pain after an operation, but their side effects can make patients sicker and lengthen hospital stays, which limits how widely they can be used.² Because of this, doctors have increasingly turned to combining different types of pain relief to reduce the need for opioids, and local anesthetics such as bupivacaine and lidocaine, which numb a specific area, have become a central part of this approach.³

A growing body of evidence suggests that nanotechnology, the use of extremely tiny materials, could help reduce or even eliminate the need for opioids in surgical patients. This could take the form of tiny drug carriers, such as fat-based bubbles that hold medicine, or patches and devices built with tiny energy-storing components.⁴

What Did the Study Find About How Well the Bupivacaine Nanoparticles Relieved Nerve Pain, and Were They Safe?

The researchers found that the drug-filled particles significantly eased pain caused by pressure or touch in both groups of rats with nerve injuries, but they did not reduce sensitivity to heat. The treatment worked by blocking signals in a specific type of slow-conducting nerve fiber that carries pain, while leaving other nerve fibers, including those that carry touch and movement signals, unaffected. Importantly, levels of the drug in the blood stayed well below the amount that would be harmful, suggesting the treatment is safe.¹

“These findings,” write the authors of the paper,¹ “suggest that bupivacaine-loaded PLGA nanoparticles represent a promising long-term therapeutic option for chronic neuropathic pain management.”

The researchers think the most likely explanation is that the slow, steady release of a small amount of bupivacaine from the particles is especially good at calming the overactive, misfiring nerves that make injured areas painfully sensitive to touch and pressure. Heat pain, on the other hand, travels along a somewhat different pathway, carried by nerve fibers with a built-in heat sensor. Blocking these signals may require a higher concentration of the drug at the site than the slow-release particles provide. It’s also possible that heat pain relies less on the “gates” in nerve cells that the drug, released this way, is best at shutting down.¹

Read More on Similar Topics
LC–MS Lipidomics Flags Diabetic Nerve Damage

References

1. Wang, T.; Tang, K.; Sun, F. et al. Bupivacaine-Loaded PLGA Nanoparticles for Long-Term Management of Chronic Neuropathic Pain. Pharmaceutics 2026, 18 (10), 1226. DOI: 10.3390/pharmaceutics18101226
2. Oderda, G.M.; Said, Q.; Evans, R.S et al. Opioid-related Adverse Drug Events in Surgical Hospitalizations: Impact on Costs and Length of Stay. Ann. Pharmacother. 2007, 41, 400–406.DOI: 10.1345/aph.1H386
3. Buvanendran, A.; Kroin, J.S. Multimodal Analgesia for Controlling Acute Postoperative Pain. Curr. Opin. Anaesthesiol. 2009, 22, 588–593.DOI: 10.1097/ACO.0b013e328330373a
4. Chelly, J.E.; Goel, S.K.; Kearns, J. et al. Nanotechnology for Pain Management. J. Clin. Med. 2024, 13, 2611. DOI: 10.3390/jcm13092611